1,015 results on '"Peggs, Karl"'
Search Results
2. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx
3. The evolution of non-small cell lung cancer metastases in TRACERx
4. The evolution of lung cancer and impact of subclonal selection in TRACERx
5. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
6. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
7. Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.
8. Donor whole blood DNA methylation is not a strong predictor of acute graft versus host disease in unrelated donor allogeneic haematopoietic cell transplantation
9. Multinational Study Assessing Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Hematopoietic Stem Cell Transplant Recipients with Cytomegalovirus Infection and Intolerance to Anti-Cytomegalovirus Therapies
10. Cytotoxic T Cells for Infections: From Donor Specific to 'Off the Shelf'
11. Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
12. Fcγ receptors and immunomodulatory antibodies in cancer
13. 1312 Identification and validation of immunogenic clonal neoantigens for personalized therapies
14. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
15. Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
16. The T cell differentiation landscape is shaped by tumour mutations in lung cancer
17. Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.
18. AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
19. Impact of baseline and week 2 and week 4 post-transplant CMV cell-mediated immunity on risk of CMV infections and mortality in allogeneic hematopoietic cell transplant recipients
20. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
21. Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD
22. Evolving adoptive cellular therapies in urological malignancies
23. Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts
24. Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation
25. Body composition and lung cancer-associated cachexia in TRACERx
26. The evolution of lung cancer and impact of subclonal selection in TRACERx
27. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
28. Cytotoxic T Cells for Infections: From Donor Specific to “Off the Shelf”
29. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party
30. Targeting the T cell receptor [beta]-chain constant region for immunotherapy of T cell malignancies
31. Supplemental Figure Legends from TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
32. Supplementary Figure from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
33. Data from TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
34. Supplementary Table from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
35. Supplemental Figures from TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
36. Supplementary Data from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
37. Supplementary Methods from Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
38. Supplementary Figures 1 - 5, Tables 1 - 3 from Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
39. A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture
40. Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Factors Associated with Durable Response
41. Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial
42. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy
43. Impact of Pretransplantation 18F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell–Depleted Allogeneic Transplantation for Hodgkin Lymphoma
44. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
45. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells
46. Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant.
47. Reprint of: Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies
48. CMV promotes recipient T-cell immunity following reduced-intensity T-cell–depleted HSCT, significantly modulating chimerism status
49. Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies
50. Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.